Spain's Aena says it has 54 flights affected by Heathrow outage
Tantrums and TIARAs
Sweden raises spending further this year to boost the economy
Novak Djokovic says he agrees and disagrees with parts of legal action launched by his players’ union
Coco Gauff double bagels Sofia Kenin in Miami Open in just 47 minutes, ‘Baby Rybakina’ records best win of career so far
How Ukraine's gas infrastructure could be of interest to Trump
FRANKFURT (Reuters) - Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular business with smaller deals.
Cytokinetics will receive 50 million euros ($53 million) upfront, plus up to 90 million euros contingent on certain development achievements, Bayer said in a statement.
Cytokinetics also stands to receive up to 490 million euros from Bayer, depending on certain sales milestones.
The deal covers certain uses of drug candidate aficamten in hypertrophic cardiomyopathy, an inherited condition that limits the heart’s pumping function.
German diversified group Bayer, which is burdened by debt, weak agriculture markets and costly litigation, has faced investor calls to boost its drug development pipeline.
In March, Bayer acquired European commercialization rights for heart drug acoramidis for up to $310 million from a group of companies.
($1 = 0.9448 euros)
(Reporting by Ludwig Burger, Editing by Friederike Heine)
